Top

Published in:

01-12-2010 | Original Paper

Trends in Adult Antipsychotic Polypharmacy: Progress and Challenges in Florida’s Medicaid Program

Authors: Robert J. Constantine, Ross Andel, Rajiv Tandon

Published in: Community Mental Health Journal | Issue 6/2010

Abstract

We studied trends in antipsychotic polypharmacy over a 4 year period in order to see if a change occurred when a statewide quality improvement program aimed at reducing the practice was implemented. Antipsychotic polypharmacy prevalence rates were calculated for eight 6-month periods for enrollees with schizophrenia and schizoaffective disorder and for those with all other diagnoses. Prevalence increased from 1/2003 to 12/2004 and then declined for 4 successive 6 month periods beginning in the 1/2005–6/05 period when the program began. Piecewise linear regression results for both diagnostic groups confirmed that the change in the likelihood of antipsychotic polypharmacy during the four 6 month periods before program implementation were significantly different than during the four 6 month periods following implementation. While it is impossible to control for the effects of all variables in evaluating the impact of any system wide intervention the data suggest that the program did help to reduce the use of antipsychotic polypharmacy.

American Psychiatric Association. (2004). Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 161(Supplement), 1–56.

Barbui, C., Nose, M., Mazzi, M. A., Thornicroft, G., Schene, A., Becker, T., et al. (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21(6), 355–362.CrossRefPubMed

Biancosino, B., Barbui, C., Marmai, L., Doná, S., & Grassi, L. (2005). Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study. International Clinical Psychopharmacology, 20(6), 305–309.CrossRefPubMed

Broekema, W. J., de Groot, I. W., & van Harten, P. N. (2007). Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharmacy World & Science, 29(3), 126–130.CrossRef

Center for Medicare Advocacy. (2008). http://www.medicareadvocacy.org.

Centorrino, F., Goren, J. L., Hennen, J., Salvatore, P., Kelleher, J. P., & Baldessarini, R. J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. American Journal of Psychiatry, 161(4), 700–706.CrossRefPubMed

Chakos, M. H., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., et al. (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE Trial. Psychiatric Services, 57(8), 1094–1101.CrossRefPubMed

Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: Implications for state mental health policy. Schizophrenia Bulletin, 28(1), 75–84.PubMed

Clinical practice guidelines. (2005). Treatment of schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 50:(13 Suppl 1), 7S–57S.

Constantine, R. J., Richard, S., Surlea, R., et al. (2006). Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist. Current Psychosis and Therapeutics Reports, 4(1), 5–11.CrossRef

Correll, C. U. (2008). Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? American Society of Clinical Psychopharmacology, 69(4), 674–675.

Elie, D., Poirier, M., Chianetta, J., Durand, M., Gregoire, C., & Grignon, S. (2009). Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology, 1–8.

Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C., & Kane, J. (2005). Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry [Electronic Resource], 5(1), 26.CrossRef

Florida Schizophrenia Guidelines. (2005). http://flmedicaidbh.fmhi.usf.edu/index.htm.

Freudenreich, O., & Goff, D. C. (2002). Antipsychotic combination therapy in schizophrenia: A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica, 106(5), 323–330.CrossRefPubMed

Ganesan, S., Taylor, R., Rabheru, K., Forbes, I., Dumontet, J., & Procyshyn, R. M. (2008). Antipsychotic polypharmacy does not increase the risk for side effects. Schizophrenia Research, 98(1), 323–324.CrossRefPubMed

Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998–2000. The Journal of Clinical Psychiatry, 65(10), 1377–1388.CrossRefPubMed

Gilmer, T. P., Dolder, C. R., Folsom, D. P., Mastin, W., & Jeste, D. V. (2007). Antipsychotic polypharmacy trends among medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatric Services, 58(7), 1007–1010.CrossRefPubMed

Goff, D. C., & Freudenreich, O. (2004). Focus on polypharmacy in schizophrenia: does anyone truly benefit? The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 7(2), 109–111.

Goren, J. L., Parks, J. J., Ghinassi, F. A., Milton, C. G., Oldham, J. M., Hernandez, P., et al. (2008). When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Joint Commission Journal on Quality and Patient Safety, 34(10), 571–582.PubMed

Hardin, J., & Hilbe, J. (2002). Generalized estimating equations. Danvers, MA: CRC Press.CrossRef

Hori, H., Noguchi, H., Hashimoto, R., Nakabayashi, T., Omori, M., Takahashi, S., Tsukue, R., Anami, K., Hirabayashi, N., Harada, S., Saitoh, O., Iwase, M., Kajimoto, O., Takeda, M., Okabe, S., & Kunugi, H. (2006). Antipsychotic medication and cognitive function in schizophrenia.

Ito, H., Koyama, A., & Higuchi, T. (2005). Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. The British Journal of Psychiatry: The Journal of Mental Science, 187, 243–247.CrossRef

Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 122–127.CrossRefPubMed

Kreyenbuhl, J., Valenstein, M., McCarthy, J. F., Ganoczy, D., & Blow, F. C. (2006). Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research, 84(1), 90–99.CrossRefPubMed

Lelliott, P., Paton, C., Harrington, M., Konsolaki, M., Sensky, T., & Okocha, C. (2002). The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin, 26(11), 411–414.CrossRef

Lewis, S. B. T. D. L., et al. (2006). Randomized controlled trial of effect of prescription of clozapine verses other second-generation antipsychotic drugs in treatment resistant schizophrenia. Schizophrenis Bulletin, 32(4), 715–723.CrossRef

Loosbrock, D. L., Zhao, Z., Johnstone, B. M., & Morris, L. S. (2003). Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. The Journal of Mental Health Policy and Economics, 6(2), 67–75.PubMed

McCue, R. E., Waheed, R., & Urcuyo, L. (2003). Polypharmacy in patients with schizophrenia. The Journal of Clinical Psychiatry, 64(9), 984–989.CrossRefPubMed

McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80(1), 19–32.CrossRefPubMed

Miller, A. L., & Craig, C. S. (2002). Combination antipsychotics: pros, cons, and questions. Schizophrenia Bulletin, 28(1), 105–109.PubMed

Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., & Valuck, R. J. (2007). Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a Multistate medicaid population, 1998–2003. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy, 29(1), 183–195.

National Institute for Clinical Excellence. (2002). Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care: Clinical Guideline 1.

Procyshyn, R. M., Kennedy, N. B., Tse, G., & Thompson, B. (2001). Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. The Canadian Journal of Psychiatry/La Revue Canadienne De Psychiatrie, 46(4), 334–339.

Rush, A. J., Crismon, M. L., Kashner, T. M., Toprac, M. G., Carmody, T. J., Trivedi, M. H., et al. (2003). Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. The Journal of Clinical Psychiatry, 64(4), 357–369.CrossRefPubMed

Sernyak, M. J., & Rosenheck, R. (2004). Clinicians’ reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry, 65(12), 1597–1600.CrossRefPubMed

Sim, K., Su, A., Fujii, S., Yang, S. Y., Chong, M. Y., Ungvari, G. S., et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58(2), 178–183.CrossRefPubMed

Stahl, S. M. (2004). Focus on Antipsychotic polypharmacy: Evidence-based prescribing or prescribing-based evidence? International Journal of Neuropsychopharmacology, 7(2), 113–116.CrossRefPubMed

Suzuki, T., Uchida, H., Tanaka, K. F., Tomita, M., Tsunoda, K., Nomura, K., et al. (2003). Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. International Clinical Psychopharmacology, 18(6), 323–329.CrossRefPubMed

Suzuki, T., Uchida, H., Watanabe, K., Nakajima, S., Nomura, K., Takeuchi, H., et al. (2008). Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: An open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Human Psychopharmacology: Clinical and Experimental, 23(6), 455–463.CrossRef

Tapp, A. (2003). Combination antipsychotic therapy in clinical practice. Psychiatric Services, 54(4), 574a.CrossRef

Tranulis, C. (2008). Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Safety, 31(1), 7–20.CrossRefPubMed

U.S. Food and Drug Administration: Center for Drug Evaluation and Research. (2007). National drug code directory. http://www.fda.gov/cder/ndc/database/default.htm.

Valuck, R. J., Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., & Allen, R. (2007). How expensive is antipsychotic polypharmacy? Experience from five US state medicaid programs. Current Medical Research and Opinion, 23(10), 2567–2576.CrossRefPubMed

Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998). Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325–329.CrossRefPubMed

Weissman, E. M. (2002). Antipsychotic prescribing practices in the veterans healthcare administration–New York metropolitan region. Schizophrenia Bulletin, 28(1), 31–42.PubMed

Zhu, B., Ascher-Svanum, H., Faries, D. E., Correll, C. U., & Kane, J. M. (2008). Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry, 8, 19.CrossRefPubMed

Title: Trends in Adult Antipsychotic Polypharmacy: Progress and Challenges in Florida’s Medicaid Program
Authors: Robert J. Constantine
Ross Andel
Rajiv Tandon
Publication date: 01-12-2010
Publisher: Springer US
Published in: Community Mental Health Journal / Issue 6/2010
Print ISSN: 0010-3853
Electronic ISSN: 1573-2789
DOI: https://doi.org/10.1007/s10597-009-9288-2

At a glance: The STEP trials

Springer Medicine

Trends in Adult Antipsychotic Polypharmacy: Progress and Challenges in Florida’s Medicaid Program

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Characteristics of Patients Referred to Psychiatric Emergency Services by Crisis Intervention Team Police Officers

A Pilot Evaluation of the In SHAPE Individualized Health Promotion Intervention for Adults with Mental Illness

A Care Planning Strategy for Traumatic Life Events in Community Mental Health and Inpatient Psychiatry Based on the InterRAI Assessment Instruments

The Use of Herbal Medications and Dietary Supplements by People with Mental Illness

The Association Between Disaster-Related Experiences and Mental Health Outcomes Among Drug Using African American Hurricane Katrina Evacuees

The Challenges in Providing Services to Clients with Mental Illness: Managed Care, Burnout and Somatic Symptoms Among Social Workers